What's Going On With Capricor Therapeutics Stock Friday?
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are trading higher on Friday. The company announced the long-term benefits of deramiocel for the treatment of duchenne muscular dystrophy (DMD).
周五，Capricor Therapeutics, Inc.（纳斯达克股票代码：CAPR）股价上涨。该公司宣布了deramiocel在治疗杜氏肌肉萎缩症（DMD）方面的长期益处。
What Happened: The biotechnology company said deramiocel increased cardiac function based on several different measures.
发生了什么：这家生物技术公司表示，根据几种不同的衡量标准，deramiocel可以增强心脏功能。
The study found improvements in left ventricular ejection fraction, left ventricular end systolic volume and left ventricular end diastolic volume. Capricor stated that these measures are considered highly applicable when projecting future outcomes.
该研究发现，左心室射血分数、左心室末期收缩压容积和左心室末舒张容积都有所改善。Capricor表示，在预测未来结果时，这些措施被认为非常适用。
The trial also demonstrated increased skeletal function, particularly increased performance of upper limb.
该试验还显示骨骼功能增强，尤其是上肢的表现得到提高。
The company based these positive findings off the ongoing HOPE-2 open label extension study. Capricor is expected to present these results at the Parent Project Muscular Dystrophy (PPMD) Annual Conference on Saturday.
该公司根据正在进行的 HOPE-2 开放标签扩展研究得出这些积极的发现。预计Capricor将在周六的家长项目肌肉萎缩症（PPMD）年会上公布这些结果。
Related Link: Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
相关链接：华尔街最准确的分析师对3只股息收益率超过3％的医疗保健股票发表了看法
CAPR Price Action: Capricor Therapeutics shares are trading 4.39% higher at $4.84 at the time of writing per data from Benzinga Pro.
CAPR价格走势：根据Benzinga Pro的数据，在撰写本文时，Capricor Therapeutics的股价上涨4.39％，至4.84美元。
Image: Shutterstock/ REDPIXEL.PL
图片：Shutterstock/REDPIXEL.PL